We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hitachi High-Tech and QIAGEN Partner to Advance Diagnostics

By LabMedica International staff writers
Posted on 05 Jul 2015
Print article
Hitachi High-Technologies Corporation (Tokyo, Japan) and QIAGEN N.V. (Venlo, The Netherlands) have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.

Under terms of the agreement both companies will bring their unique strengths to the collaboration: Hitachi High-Technologies brings its leadership in industrialized instrument development and manufacturing technologies, especially for life sciences and in vitro diagnostics (IVD), while QIAGEN brings its leadership in molecular sample-to-insight solutions for life sciences and clinical diagnostics.

Initial projects involve developing new automation systems based on PCR and NGS (next-generation sequencing) technologies. Both parties agreed that the collaboration could be expanded in the future to involve co-commercialization of products in specific geographic markets. Further terms of the collaboration are confidential.

“QIAGEN and Hitachi High-Technologies share much the same corporate culture such as customer focus as well as a commitment to technology and quality leadership,” said Yasukuni Koga, head of Medical Systems Sales and Marketing Division, Hitachi High-Technologies, “We believe those are crucial for the collaboration to achieve a meaningful position in the rapidly changing and highly competitive markets of in vitro diagnostics and life sciences, applying genetic engineering. Moreover, developing a co-commercialization collaboration with distribution and customer service in specific geographical regions would be highly accepted by customers of each company.”

“This new strategic partnership with Hitachi High-Technologies will form a very powerful platform to create new molecular testing solutions. Hitachi High-Technologies is a recognized leader in industrial automation and has a proven track record of innovation as well as a significant presence in the Asia-Pacific region,” said Thierry Bernard, senior vice president, head of Molecular Diagnostics Business Area, QIAGEN, “Combining the NGS-related and other molecular know-how of QIAGEN with the instrumentation expertise of Hitachi High-Technologies will enable us to bring innovative automation solutions to customers all over the world and across the continuum from basic research through to routine molecular diagnostics.”

Related Links:

Hitachi High-Technologies
QIAGEN N.V.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: A view of the brain with perturbation expression (Photo courtesy of Scripps Research)

Groundbreaking CRISPR Screen Technology Rapidly Determines Disease Mechanism from Tissues

Thanks to over a decade of advancements in human genetics, scientists have compiled extensive lists of genetic variations linked to a wide array of human diseases. However, understanding how a gene contributes... Read more